Telmisartan versus EnalapRil In heart failure with redUced ejection fraction patients with Moderately impaired kidney Functions; randomized controlled trial: “TRIUMF trial”

Telmisartan versus EnalapRil In heart failure with redUced ejection fraction patients with Moderately impaired kidney Functions; randomized controlled trial: “TRIUMF trial”

Abstract Background When heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) co-exist, Renin angiotensin-aldosterone system inhibitors (RAASi) are often underutilized for the fear of worsening renal function (WRF). Telmisartan is a RAASi characteristic for a favorab...

Full description

Bibliographic Details
Main Authors: Ahmad Samir, Salma Aboel-Naga, Ahmed Shehata, Magdy Abdelhamid
Format: Article
Language:English
Published: SpringerOpen 2023-08-01
Series:The Egyptian Heart Journal
Subjects:
Telmisartan
Enalapril
Heart failure with reduced ejection fraction HFrEF
Chronic kidney disease CKD
Worsening renal function WRF
Online Access:https://doi.org/10.1186/s43044-023-00398-7

Internet

https://doi.org/10.1186/s43044-023-00398-7

Similar Items